Manifold, an AI-powered clinical research platform, announced a $15 million Series A. TQ Ventures led this funding round. It also included new investors Calibrate Ventures and SK Ventures, notable founders and CEOs, including healthcare leader Dr. Sachin H. Jain, and existing investors, including TTCER Partners. Additional investors and advisors include Dr. Gaurav Singal (former Chief Data Officer, Foundation Medicine), Eric Just (former SVP and General Manager, Health Catalyst), Amar Kendale (former Chief Product Officer), Livongo/Teladoc, Andrew Bialecki (CEO & Co-Founder, Klaviyo), Brad Porter (CEO & Founder, Collaborative Robotics and former VP Robotics, Amazon), Steve Fredette (President & Co-Founder, Toast), Jon Karlen (Chairman & Founder, Acadian Software), and Pravin Soni (former CTO & Co-Founder, Elevation Pharma).
The company’s platform streamlines the manual workflows of modern study and data management. Manifold has helped research teams reduce the time to insights from months to minutes.
Legacy workflows could delay research advances by years – preventing improvements in patient outcomes. And Manifold’s AI-powered platform accelerates modern research studies, enabling researchers to rapidly collect, curate, and analyze comprehensive patient data.
As healthcare data grows and becomes more complex, an AI-powered technology foundation becomes essential to creating a unified and analysis-ready view of each patient’s journey. For the first time, Manifold enables research teams to enroll and engage study participants, harmonize and curate longitudinal data, find and analyze multimodal datasets, and collaborate securely across organizations—all in an easy-to-use platform.
Manifold’s technology has already shown promising results in early collaborations with the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Winship Cancer Institute of Emory University, etc. And one research organization unified over 11 terabytes of multimodal data – which spans 1.5 million patients – into a single platform, streamlining study and data operations, increasing research output, and unlocking opportunities for collaboration at scale.
KEY QUOTES:
“Cancer research has had a technology infrastructure problem for years. As research organizations access more data from EHRs to genetic sequencing to imaging, research datasets are getting larger and more disparate. Researchers lose precious time and resources trying to connect patient data from these disparate systems into a unified patient view. Our partnership with Manifold on a modern technology infrastructure is enabling us to respond to far more research requests with less manual effort and cost.”
– Anna Maria V. Storniolo, MD, Medical Director, Biospecimen Collection and Banking Core, IU Melvin and Bren Simon Comprehensive Cancer Center
“Manifold is transforming clinical research by providing research organizations with purpose-built technology infrastructure for this new era. Our vision is to make it ten times faster and one-tenth the cost to conduct modern research studies that unlock insights never-before possible.”
– Vinay Seth Mohta, CEO and Co-Founder of Manifold
“Manifold is tackling new challenges created by big data increasingly available about every patient. In doing that, they are greatly improving productivity in clinical research today and also laying the groundwork for an industry cloud for personalized medicine in the future.”
– Andrew Marks, Co-Founder and Managing Partner, TQ Ventures
